Pterostilbene

Also known as: trans-Pterostilbene, 3,5-Dimethoxy-4'-hydroxystilbene

A blueberry polyphenol with small, short human studies and an LDL-cholesterol increase in a monotherapy trial.

A hand-carved linocut study of five whole blueberries on cream paper.
Editorial illustration

Pterostilbene is a polyphenol found in blueberries and studied in oral supplements. One small trial reported lower blood pressure at its higher dose and higher LDL cholesterol with pterostilbene alone. Human evidence remains limited for health benefits, and a combination study measuring NAD+ leaves pterostilbene's individual contribution unresolved.1, 3

  • In the metabolic trial, pterostilbene monotherapy increased LDL cholesterol by an estimated 17.1 mg/dL.1
  • The higher-dose group received 125 mg twice daily for six to eight weeks. The study measured blood pressure and laboratory outcomes.1
  • The NAD+ trial combined 50 or 100 mg/day pterostilbene with 250 or 500 mg/day nicotinamide riboside in 120 older adults.3

What is Pterostilbene?

The human literature includes separate reports from the same 80-person metabolic trial and an eight-week study combining pterostilbene with nicotinamide riboside. Counting the two reports as separate trials would overstate the number of independently studied participants.1, 2, 3

Where it comes from

Natural sources

  • Pterostilbene occurs in blueberries.

How it's made

The cited trials used specified oral preparations. An ingredient name alone leaves purity and finished-product equivalence to be established.

What it does in products

  • Polyphenol in oral supplements
  • Component of combinations studied for NAD+ biomarkers

Benefits

Blood-pressure findings need replication

limited evidence

A short metabolic study offers a preliminary signal with a relevant lipid trade-off.1

The four-arm trial enrolled 80 adults with elevated cholesterol. Its 250 mg/day arm reduced blood pressure, while pterostilbene monotherapy raised LDL. Follow-up lasted six to eight weeks and assessed surrogate outcomes, leaving effects on cardiovascular events uncertain.

Evidence scope and limitations

Short oral metabolic and safety studies plus one nicotinamide-riboside combination trial.

  • The two Riche reports share an 80-person trial cohort. They supply complementary outcomes without independent replication.
  • The selected trials are short and primarily assess biomarkers. Long-term clinical benefit, pregnancy safety and broad interaction profiles remain uncertain.
  • The combination study was checked through original indexed text after publisher access restrictions. Its design limits attribution to pterostilbene alone.

Evidence last checked: 2026-11-14

Side effects & safety

LDL-cholesterol increase (varies)The monotherapy finding is relevant when assessing cardiovascular claims. A favorable blood-pressure result alone gives an incomplete account of the trial.

Safety considerations

  • The selected short adult trials leave pregnancy and breastfeeding safety insufficiently characterized. Discuss supplement use with a qualified health professional.
  • Review concurrent medicines and supplements with a clinician or pharmacist. The selected studies provide limited information on clinically important interactions.
1, 2, 4

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In short oral trials

The metabolic study tested 100 or 250 mg/day pterostilbene alone, plus a separate grape-extract combination, over six to eight weeks. The NR combination study used 50 or 100 mg/day pterostilbene for eight weeks. These amounts describe the tested preparations and remain unsupported as a universal long-term intake target.

1, 3

Regulatory status

  • FDA's dietary-supplement framework places safety and labeling responsibilities on manufacturers. U.S. supplements enter the market without routine FDA premarket efficacy approval, and a trial of a biomarker does not establish an authorized disease-treatment claim.
4

What the NAD+ result can answer

The eight-week study enrolled adults aged 60–80 and tested a combination of nicotinamide riboside and pterostilbene. Whole-blood NAD+ increased. The combination design leaves the contribution of each ingredient unresolved.

NAD+ concentration is a biomarker. This study's duration and outcomes leave lifespan extension and prevention of age-related disease unestablished. Claims about longevity need clinical outcomes beyond the measured blood marker.

3

Frequently asked questions

Are the 2013 safety paper and 2014 metabolic paper independent evidence?

Both describe NCT01267227. The safety paper evaluated short-term laboratory and adverse-event measures, while the metabolic report includes the LDL increase. Their shared cohort should be counted once when assessing replication.2, 1

The bottom line

Weigh the LDL finding alongside preliminary metabolic results and keep combination biomarkers within their measured scope.

References

  1. Riche DM, et al.. Pterostilbene on Metabolic Parameters: A Randomized, Double-Blind, and Placebo-Controlled Trial. Evidence-Based Complementary and Alternative Medicine (2014) · randomized trial · PMID 25057276; DOI 10.1155/2014/459165; NCT01267227; 80-person trial, six-to-eight-week outcomes and LDL finding checked in original text
  2. Riche DM, McEwen CL, Riche KD, et al.. Analysis of Safety from a Human Clinical Trial with Pterostilbene. Journal of Toxicology (2013) · randomized trial · DOI 10.1155/2013/463595; safety report from the same NCT01267227 cohort as the 2014 metabolic paper, not an independent trial
  3. Dellinger RW, et al.. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. npj Aging and Mechanisms of Disease (2017) · randomized trial · PMID 29184669; DOI 10.1038/s41514-017-0016-9; 120 adults aged 60–80, eight-week combination study; original indexed text checked after publisher access restrictions
  4. Questions and Answers on Dietary Supplements. U.S. Food and Drug Administration · government guidance · Undated current agency resource checked November 14, 2026 for premarket review and professional-consultation framework

Revision history

  1. Initial AI-assisted source compilation with claim-level citations, formulation distinctions and explicit evidence limitations; not independent medical review.